Impact of Relacorilant on Blood Pressure and Antihypertensive Medication Burden in Patients With Hypercortisolism and Hypertension: Results From the GRACE Study

Summary

• In GRACE, rapid and sustained improvements in blood pressure were observed with relacorilant treatment during the open-label phase in participants with endogenous hypercortisolism and hypertension
• Blood pressure improvements were maintained with relacorilant during the randomized-withdrawal phase, whereas blood pressure deteriorations occurred in the placebo arm
• Relacorilant treatment also resulted in decreases/discontinuations in antihypertensive medication
• Due to relacorilant’s specificity for the glucocorticoid receptor and its mechanism of action, the observed efficacy was seen:
  • Without cases of relacorilant-induced irregular vaginal bleeding with endometrial hypertrophy
  • Without increases in cortisol concentrations and relacorilant-induced hypokalemia
  • Without reported cases of adrenal insufficiency
  • Without independently-confirmed QT prolongation

Download PosterDownload presentation